110 related articles for article (PubMed ID: 10584897)
1. Response to interferon alfa-2b therapy in mutitransfused children with beta-thalassemia and chronic hepatitis C.
Spiliopoulou I; Repanti M; Katinakis S; Karana-Ginopoulou A; Papanastasiou DA
Eur J Clin Microbiol Infect Dis; 1999 Oct; 18(10):709-15. PubMed ID: 10584897
[TBL] [Abstract][Full Text] [Related]
2. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha treatment of chronic hepatitis C virus infection in children.
Jonas MM; Ott MJ; Nelson SP; Badizadegan K; Perez-Atayde AR
Pediatr Infect Dis J; 1998 Mar; 17(3):241-6. PubMed ID: 9535253
[TBL] [Abstract][Full Text] [Related]
4. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
6. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
[TBL] [Abstract][Full Text] [Related]
7. Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group.
Keeffe EB; Dusheiko GM; James SP; Mullen KD; Everson GT; Pimstone NR; Donovan J; Albert D
Cytokines Cell Mol Ther; 1999 Dec; 5(4):207-10. PubMed ID: 10850384
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
9. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.
Keeffe EB; Dusheiko GM; Tong MJ; Hollinger FB; Heathcote EJ; McHutchison J; Albert D
Cytokines Cell Mol Ther; 1999 Dec; 5(4):211-6. PubMed ID: 10850385
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
11. Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy.
Jorquera F; Almar M; Díaz-Golpe V; Olcóz JL; García-Fernández A; González-Gallego J
Am J Gastroenterol; 2001 Aug; 96(8):2456-61. PubMed ID: 11513190
[TBL] [Abstract][Full Text] [Related]
12. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Interferon A-2b monotherapy in Β-thalassemics with chronic hepatitis C.
Kalafateli M; Kourakli A; Gatselis N; Lambropoulou P; Thomopoulos K; Tsamandas A; Christofidou M; Zachou K; Jelastopoulou E; Nikolopoulou V; Symeonidis A; Dalekos GN; Lambropoulou-Karatza C; Triantos C
J Gastrointestin Liver Dis; 2015 Jun; 24(2):189-96. PubMed ID: 26114179
[TBL] [Abstract][Full Text] [Related]
14. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
[TBL] [Abstract][Full Text] [Related]
15. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
[TBL] [Abstract][Full Text] [Related]
16. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
17. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.
Younossi ZM; Mullen KD; Hodnick S; Barnes DS; Carey WD; McCullough AC; Easley K; Gramlich T; Liebermann BY
J Clin Gastroenterol; 2003; 36(5):427-30. PubMed ID: 12702987
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha treatment of chronic hepatitis C in children with hemophilia.
Ko JS; Choe YH; Kim EJ; Lee EH; Jang JJ; Seo JK
J Pediatr Gastroenterol Nutr; 2001 Jan; 32(1):41-4. PubMed ID: 11176323
[TBL] [Abstract][Full Text] [Related]
19. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
Sievert W; Pianko S; Warner S; Bowden S; Simpson I; Bowden D; Locarnini S
Am J Gastroenterol; 2002 Apr; 97(4):982-7. PubMed ID: 12003436
[TBL] [Abstract][Full Text] [Related]
20. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
Nelson DR; Rustgi V; Balan V; Sulkowski MS; Davis GL; Muir AJ; Lambiase LR; Dickson RC; Weisner RH; Fiscella M; Cronin PW; Pulkstenis E; McHutchison JG; Subramanian GM
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):212-8. PubMed ID: 19061971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
